Türkiye among top investment destinations for drugmaker Lilly

Sabah - US pharmaceutical company Eli Lilly has shortlisted Türkiye for its future investments, according to the company’s Senior Vice-President Bart Peterson. Known for its diabetes and cancer treatment drugs, Lilly is reported to be in talks for a possible partnership with a Turkish company, Nevzat Ibrahim.

“Lilly considers Türkiye to be a top priority investment location,” said Peterson during a visit to Türkiye, underlining Türkiye’s economic growth and large domestic market. “Türkiye is a major market with an advanced healthcare system. The investment environment is developing rapidly as well,” he noted, declining to comment on possible partnership deals.

“Our investment focus is on having a wide range of products. We are in a fast growth period in Türkiye and the government’s steps in the last few years have increased the quality and accessibility of healthcare services significantly,” he added.
Türkiye; healthcare sector; turkish healhcare industry; turkish drug maker; lilly; mustafa nevzat; Türkiye pharmaceuticals; Türkiye healthcare invesment; bart peterson; turkish pharmaceutical market